AbbVie has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) for the use of its venetoclax drug to treat acute myeloid leukaemia (AML), an aggressive blood cancer.

The application seeks approval for venetoclax’s combination with a hypomethylating agent (HMA) or low-dose cytarabine (LDAC) in newly diagnosed patients who are ineligible for intensive chemotherapy.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Venetoclax is an oral B-cell lymphoma-2 (BCL-2) inhibitor being developed by AbbVie in collaboration with Roche. It already secured approval for the treatment of another blood cancer, chronic lymphocytic leukaemia (CLL).

The sNDA includes results obtained during the investigational M14-358 and M14-387 clinical trials.

M14-358 is a Phase Ib trial designed to assess venetoclax in combination with an HMA (azacitidine or decitabine), while M14-387 is a Phase I/II trial of the drug in conjunction with LDAC.

“The data submitted to the FDA may potentially reshape how AML is treated.”

AbbVie research and development executive vice-president and chief scientific officer Michael Severino said: “AML is an especially lethal and aggressive form of blood cancer with limited advances in care in three decades and few treatment options for patients ineligible for intensive chemotherapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The data submitted to the FDA may potentially reshape how AML is treated. We look forward to working with the FDA and other health authorities during the review of these data.”

Venetoclax secured four FDA breakthrough therapy designations, including combination with an HMA and with LDAC for treatment-naïve AML patients.

The drug also obtained the FDA approval as a monotherapy or in combination with rituximab for relapsed/refractory (R/R) CLL or small lymphocytic lymphoma (SLL) patients who previously received at least one therapy.

It is also being investigated for the treatment of various hematologic cancers such as multiple myeloma (MM), non-Hodgkin lymphoma (NHL) and myelodysplastic syndrome (MDS).